In agreement with our findings, a recent study identified the HLA-E*0101 variant as a protective factor for EBV+ cHL (25) and EBV+PTLD (16), which further confirms that the HLA-E genotype impacts the development of EBV-associated lymphomas. This evidence concerns the gene HLA-E and post-transplant lymphoproliferative disease.